Active Stocks
Fri Jun 27 2025 15:59:58
  1. Tata Steel share price
  2. 161.40 0.56%
  1. Itc share price
  2. 418.95 -0.33%
  1. Tata Motors share price
  2. 686.70 0.54%
  1. Ntpc share price
  2. 337.95 0.24%
  1. State Bank Of India share price
  2. 805.40 1.05%
Business News/Market/Market Stats/    Alivus Life Sciences

ALIVUS LIFE SCIENCES SUMMARY

Alivus Life Sciences is trading 0.45% upper at Rs 999.80 as compared to its last closing price. Alivus Life Sciences has been trading in the price range of 1008.95 & 992.00. Alivus Life Sciences has given 1.82% in this year & 0.31% in the last 5 days.

 

Alivus Life Sciences has TTM P/E ratio 27.31 as compared to the sector P/E of 22.43. There are 3 analysts who have initiated coverage on Alivus Life Sciences. There are 1 analysts who have given it a strong buy rating & 2 analysts have given it a buy rating. 0.00 analysts have given the stock a sell rating.

 

The company posted a net profit of 141.87 Crores in its last quarter.

 

Listed peers of Alivus Life Sciences include Natco Pharma (1.38%), Sanofi India (0.08%), Alivus Life Sciences (0.45%) etc.

 

Alivus Life Sciences has a 74.99% promoter holding & 25.01% public holding.

FAQs about Alivus Life Sciences

Alivus Life Sciences is trading at 999.80 as on 27 Jun, 2025 3:28:36 PM. This is 0.45% upper as compared to its previous closing price of 995.35
The market capitalization of Alivus Life Sciences is 12203.45 Cr as on 27 Jun, 2025 3:28:36 PM.
The average broker rating on Alivus Life Sciences is Strong Buy. The breakup of analyst rating is given below -
  • 0.00 analysts have given a strong sell rating
  • 0.00 analysts have given a sell rating
  • 0.00 analysts have given a hold rating
  • 2 analysts have given a buy rating
  • 1 analysts have given a strong buy rating
The 52 wk high for Alivus Life Sciences is 1335.00 whereas the 52 wk low is 820.05
Alivus Life Sciences can be analyzed on the following key metrics -
  • TTM P/E: 27.31
  • Sector P/E: 22.43
  • Dividend Yield: 0.5%
  • D/E ratio: -
Alivus Life Sciences reported a net profit of 485.63 Cr in 2025.
Recommended For You